De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients

Infection

Volumn 39, Issue 4, 2011, Pages 319-325

  Shime, N ^a,b   Satake, S ^a   Fujita, N ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibiotic sensitive pathogens; Antimicrobial therapy; Bacteraemia; De escalation strategy; Immunocompetent

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DE ESCALATION STRATEGY; DEATH; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; IMMUNOCOMPETENCE; INFANT; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PENICILLIN RESISTANCE; TREATMENT DURATION;

EID: 85027938109     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0116-6     Document Type: Article

References (30)

1. Pittet D, Tarara D, Wenzel RP, et al. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598-601.
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP, et al. Noso-comial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol. 2000;21:510-5. (Pubitemid 30647154)
3. Harbarth S, Ferrière K, Hugonnet S, Ricou B, Suter P, Pittet D, et al. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg. 2002;137: 1353-9. (Pubitemid 35429592)
4. Leibovici L, Drucker M, Konigsberger H, Samra Z, Harrari S, Ashkenazi S, Pitlik SD, et al. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Infect Dis. 1997;29: 71-5.
5. Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, Thys JP, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis. 1999;29:60-6. (Pubitemid 29336802)
6. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH, et al. The influence of inadequate antimicrobial treatment of blood-stream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-55. (Pubitemid 30485502)
7. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529-35. (Pubitemid 37352798)
8. Sostarich AM, Zolldann D, Haefner H, Luetticken R, Schulze-Roebecke R, Lemmen SW. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay. Infection. 2008;36:31-5.
9. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Ja-eschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, et al. Surviving Sepsis Campaign: international guidelines for man-agement of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-327.
10. Dellit TH, Owens RC, Mc Gowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Car-penter CF, Brennan PJ, Billeter M, Hooton TM, Infectious Dis-eases Society of America, Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;15(44):159-77. (Pubitemid 46084814)
11. Kuti EL, Patel AA, Coleman CI, et al. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-asso-ciated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23:91-100. (Pubitemid 351400347)
12. Philippe E, Weiss M, Shultz JM, Yeomans F, Ehrenkranz NJ, et al. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care. 1999; 7:83-7.
13. Patterson JE. Antibiotic utilization: is there an effect on antimi-crobial resistance? Chest. 2001;119:426S-30S. (Pubitemid 32163813)
14. Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J, et al. Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations. Infection. 2009;37: 432-7.
15. Niederman MS. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Car. 2006;12:452-7. (Pubitemid 44341712)
16. Lisboa T, Rello J, et al. De-escalation in lower respiratory tract infections. Curr Opin Pulm Med. 2006;12:364-8. (Pubitemid 44315783)
17. Kollef MH, Morrow LE, Niederman MS, Leeper KV, Anzueto A, Benz-Scott L, Rodino FJ, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129:1210-8.
18. Eachempati SR, Hydo LJ, Shou J, Barie PS, et al. Does de-escalation of antibiotic therapy for ventilator-associated pneu-monia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66:1343-8.
19. Corona A, Wilson AP, Grassi M, Singer M, et al. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy. J Anti-microb Chemother. 2004;54:809-17. (Pubitemid 39386736)
20. Corona A, Wilson AP, Grassi M, Singer M, et al. Short-course monotherapy strategy for treating bacteremia in the critically ill. Minerva Anestesiol. 2006;72:841-57. (Pubitemid 44650754)
21. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR, et al. STIC study group: efficacy and safety of sequential intravenous/oral moxi-floxacin vs intravenous/oral amoxicillin/clavulanate for compli-cated skin and skin structure infections. Infection. 2009;37: 407-17.
22. De Waele JJ, Ravyts M, Depuydt P, Blot SI, Decruyenaere J, Vogelaers D, et al. De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality? J Crit Care. 2010;25:641-6.
23. Rello J, Vidaur L, Sandiumenge A, Rodríguez A, Gualis B, Boque C, Diaz E, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32:2183-90. (Pubitemid 39491796)
24. Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, A-lepopoulou E, Kartali-Ktenidou S, Manolas K, et al. De-escala-tion therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med. 2007;33: 1533-40. (Pubitemid 47312455)
25. Donaldson AD, Barkham T, et al. De-escalation for amoxicillin-susceptible Escherichia coli: easier said than done. J Hosp Infect. 2010;74:304-5.
26. Minton J, Clayton J, Sandoe J, Mc Gann H, Wilcox M, et al. Improving early management of bloodstream infection: a quality improvement project. BMJ. 2008;336(7641):440-3. (Pubitemid 351310891)
27. Barlow G, Nathwani D, Myers E, Sullivan F, Stevens N, Duff R, Davey P, et al. Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia. J Antimicrob Chemother. 2008;61:442-51.
28. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-65. (Pubitemid 29493800)
29. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis. 2007;45(Suppl 3):S177-83. (Pubitemid 47378904)
30. Pea F, Viale P, et al. Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococ-cus aureus ventilator-associated pneumonia? J Trauma. 2009;67: 893-4.